PSAB
MCID: PLY068
MIFTS: 41

Polysubstance Abuse (PSAB)

Categories: Genetic diseases

Aliases & Classifications for Polysubstance Abuse

MalaCards integrated aliases for Polysubstance Abuse:

Name: Polysubstance Abuse 57 54 70
Polysubstance Abuse, Susceptibility to 57 29 39
Drug Addiction 57 54
Drug Addiction, Susceptibility to 57
Drug Dependence 70
Psab 57

Classifications:



External Ids:

OMIM® 57 606581
UMLS 70 C0747752 C1510472

Summaries for Polysubstance Abuse

MalaCards based summary : Polysubstance Abuse, also known as polysubstance abuse, susceptibility to, is related to drug dependence and withdrawal disorder. An important gene associated with Polysubstance Abuse is FAAH (Fatty Acid Amide Hydrolase), and among its related pathways/superpathways are Circadian entrainment and Monoamine GPCRs. The drugs Ketamine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and nervous system

More information from OMIM: 606581

Related Diseases for Polysubstance Abuse

Diseases related to Polysubstance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 drug dependence 30.6 DRD3 DRD2 CNR1
2 withdrawal disorder 30.5 FAAH CNR1
3 opioid addiction 30.1 DRD2 COMT
4 alcohol use disorder 29.8 DRD3 DRD2 COMT
5 opiate dependence 29.8 DRD3 DRD2
6 substance abuse 29.8 DRD3 DRD2 COMT CNR1
7 chronic pain 29.7 COMT CNR1
8 heroin dependence 29.7 DRD2 COMT
9 tobacco addiction 29.7 DRD3 DRD2 COMT
10 traumatic brain injury 29.7 DRD2 COMT
11 brain injury 29.7 DRD2 COMT
12 mental depression 29.4 DRD2 COMT
13 pathological gambling 29.4 DRD3 DRD2 COMT
14 alexithymia 29.4 DRD2 COMT
15 obsessive-compulsive disorder 29.4 DRD3 DRD2 COMT
16 endogenous depression 29.4 DRD2 COMT
17 social phobia 29.3 DRD2 COMT
18 borderline personality disorder 29.3 DRD2 COMT
19 cocaine dependence 29.3 DRD3 DRD2 COMT CNR1
20 personality disorder 29.3 DRD3 DRD2 COMT
21 post-traumatic stress disorder 29.2 FAAH DRD2 COMT CNR1
22 bulimia nervosa 29.2 DRD2 COMT
23 pain agnosia 29.2 FAAH COMT CNR1
24 psychotic disorder 29.2 DRD3 DRD2 COMT CNR1
25 major depressive disorder 29.1 DRD3 DRD2 COMT
26 body mass index quantitative trait locus 11 29.1 FAAH DRD2 COMT CNR1
27 impulse control disorder 29.1 DRD3 DRD2 COMT
28 movement disease 29.0 DRD3 DRD2 COMT
29 bipolar disorder 29.0 DRD3 DRD2 COMT CNR1
30 dystonia 29.0 DRD3 DRD2 COMT
31 anorexia nervosa 28.9 COMT CNR1
32 cannabis abuse 28.9 FAAH DRD2 COMT CNR1
33 eating disorder 28.9 FAAH DRD3 DRD2 COMT CNR1
34 anxiety 28.9 FAAH DRD2 COMT CNR1
35 attention deficit-hyperactivity disorder 28.9 FAAH DRD3 DRD2 COMT
36 substance dependence 28.9 DRD3 DRD2 COMT CNR1
37 mood disorder 28.9 DRD3 DRD2 COMT CNR1
38 autism 28.8 DRD3 DRD2 COMT CNR1
39 autism spectrum disorder 28.8 DRD3 DRD2 COMT CNR1
40 disease of mental health 28.7 FAAH DRD3 DRD2 COMT CNR1
41 schizophrenia 28.7 FAAH DRD3 DRD2 COMT CNR1
42 gilles de la tourette syndrome 28.6 DRD3 DRD2 COMT CNR1
43 alcohol dependence 28.5 FAAH DRD3 DRD2 COMT CNR1
44 migraine with or without aura 1 28.3 FAAH DRD3 DRD2 COMT CNR1
45 endocarditis 10.3
46 helix syndrome 10.3
47 smoking as a quantitative trait locus 3 10.2
48 viral hepatitis 10.2
49 avoidant personality disorder 10.2
50 body mass index quantitative trait locus 9 10.1

Graphical network of the top 20 diseases related to Polysubstance Abuse:



Diseases related to Polysubstance Abuse

Symptoms & Phenotypes for Polysubstance Abuse

Clinical features from OMIM®:

606581 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Polysubstance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 CNR1 COMT DRD2 DRD3 FAAH
2 nervous system MP:0003631 9.02 CNR1 COMT DRD2 DRD3 FAAH

Drugs & Therapeutics for Polysubstance Abuse

Drugs for Polysubstance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
6
Methadone Approved Phase 4 76-99-3 4095
7
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
8 Sodium Channel Blockers Phase 4
9 Anesthetics, Dissociative Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Diuretics, Potassium Sparing Phase 4
12 Neurotransmitter Agents Phase 4
13 Anesthetics Phase 4
14 Anticonvulsants Phase 4
15 Hypnotics and Sedatives Phase 4
16 Psychotropic Drugs Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Anti-Anxiety Agents Phase 4
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 Gastrointestinal Agents Phase 4
22 Antiemetics Phase 4
23 GABA Modulators Phase 4
24 Opiate Alkaloids Phase 4
25
Heroin Phase 4 5462328
26
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
27
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
29
Succinylcholine Approved Phase 2, Phase 3 306-40-1 5314
30
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
32
Ketorolac Approved Phase 2, Phase 3 74103-06-3, 66635-83-4 3826
33
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
34
Ondansetron Approved Phase 2, Phase 3 99614-02-5 4595
35
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
36 GABA Agonists Phase 2, Phase 3
37 calcium channel blockers Phase 2, Phase 3
38 Calcium, Dietary Phase 2, Phase 3
39 Adrenergic alpha-Agonists Phase 2, Phase 3
40 Antihypertensive Agents Phase 2, Phase 3
41 Adrenergic Agents Phase 2, Phase 3
42 Sympatholytics Phase 2, Phase 3
43 Adrenergic Agonists Phase 2, Phase 3
44 Detox adjuvant Phase 2, Phase 3
45 Anesthetics, Inhalation Phase 2, Phase 3
46 BB 1101 Phase 2, Phase 3
47 Charcoal Phase 3
48
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
49
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594
50
Zonisamide Approved, Investigational Phase 1, Phase 2 68291-97-4 5734

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Unknown status NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
2 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
3 A PHASE 4, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE-CONTROLLED, SINGLE-DOSE, FIVE-WAY CROSSOVER STUDY EVALUATING THE ABUSE POTENTIAL OF THREE DOSES OF NEURONTIN(REGISTERED) TAKEN ORALLY IN HEALTHY, NON-DRUG DEPENDENT PARTICIPANTS WITH SEDATIVE DRUG ABUSE EXPERIENCE Not yet recruiting NCT04570436 Phase 4 gabapentin 600 mg;gabapentin 1200 mg;gabapentin 1800 mg;diazepam 20 mg
4 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
5 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
6 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
7 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
8 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
9 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
10 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
11 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
12 Improving Treatment Outcomes for Prescription Opioid Dependence Recruiting NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
13 Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient Recruiting NCT03367988 Phase 2, Phase 3 Opioid Anesthesia;Opioid-free Anesthesia
14 The Nicholson Science Pheromone Trial Not yet recruiting NCT03394911 Phase 3
15 Addiction Treatment Dropout Prevention - Impact of Online Patient Feedback (OQ-45.2) to Therapist Unknown status NCT01891045 Phase 2
16 Youth Drug Abuse Family and Cognitive-Behavioral Therapy Completed NCT00198874 Phase 2
17 Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse Completed NCT01137890 Phase 1, Phase 2 Zonisamide;Placebo;Cocaine Hydrochloride
18 Clinical Trial of Topiramate for Cocaine Addiction Completed NCT00685178 Phase 2 topiramate;placebo + NonCR
19 CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component Completed NCT00842036 Phase 2
20 Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients. Completed NCT02091167 Phase 2
21 Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
22 Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse Completed NCT01385553 Phase 1, Phase 2
23 Effectiveness of Extended Treatment for Drug Dependence - City Supplement Completed NCT01153464 Phase 2
24 Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail Completed NCT00618280 Phase 1, Phase 2 nicotine nasal spray
25 A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer Completed NCT00952497 Phase 2 Cisplatin, Capecitabine, Telatinib
26 Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone Recruiting NCT04003948 Phase 2 Ibogaine Hydrochloride
27 Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study Recruiting NCT02037126 Phase 2 Psilocybin;Diphenhydramine
28 Neurocognitive Empowerment for Addiction Treatment (NEAT) in People With Opioid Use Disorder and Amphetamine Use Disorder: A Randomized Clinical Trial Recruiting NCT03922646 Phase 1, Phase 2
29 Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use Terminated NCT00430573 Phase 2 D-cycloserine;Placebo
30 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders
31 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) Withdrawn NCT00000327 Phase 2 Heroin Dependence
32 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III Withdrawn NCT00000328 Phase 2 Opioid-Related Disorders
33 Developing a Smoking Cessation Intervention for Methadone Maintained Smokers Completed NCT01393392 Phase 1
34 Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray Completed NCT01136642 Phase 1 Nicotrol
35 Integration of the Therapeutic Workplace in Drug Court Completed NCT00607360 Phase 1
36 Drug Discrimination in Methadone-Maintained Humans Study 3 Completed NCT01068847 Phase 1 2-4 of the drugs listed below
37 Drug Discrimination in Methadone-Maintained Humans Study 1 Completed NCT00593463 Phase 1 Cycloserine;Diltiazem;Gabapentin;Isradipine;Naloxone;Nifedipine;Placebo;Verapamil
38 Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder Completed NCT00218725 Phase 1
39 Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution Completed NCT01560221 Phase 1 Methadone;Buprenorphine
40 Effect of Varenicline on a Laboratory Model of Tobacco Addiction and on Withdrawal-Induced Cognitive Impairment Withdrawn NCT01309685 Phase 1 Varenicline
41 TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer Withdrawn NCT04073160 Phase 1 Tremelimumab;Durvalumab;Intravesicular Therapy
42 Brain Electrophysiological Study(EEG/ERP) on Opiate Addicts Treating by Bilateral NAc/ALIC Deep Brain Stimulation Unknown status NCT02594306
43 Cohort Study on People Who Inject Drugs in Senegal Unknown status NCT03459768
44 Clinician-patient Interaction During Addiction Consultation and Drug Overdose Risk Unknown status NCT01769651
45 Study of the Impact of Two Health Prevention Strategies on Students in the Auvergne-Rhône Alpes Region (I2S-Health Prevention) Unknown status NCT03759626
46 Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 Completed NCT03048552
47 A Mindfulness-Based Intervention for Youth With Concurrent Disorders Completed NCT00244699
48 Effect of Oxytocin on Craving and Therapy Response in Marijuana-dependent Individuals Completed NCT01827332 Oxytocin;Saline
49 Linking Russian Narcology & HIV Care to Enhance Treatment, Retention, & Outcomes Completed NCT01612455
50 Effect of Oxytocin on Stress Response in Marijuana-dependent Individuals Completed NCT01335789 Oxytocin;Saline

Search NIH Clinical Center for Polysubstance Abuse

Genetic Tests for Polysubstance Abuse

Genetic tests related to Polysubstance Abuse:

# Genetic test Affiliating Genes
1 Polysubstance Abuse, Susceptibility to 29 FAAH

Anatomical Context for Polysubstance Abuse

MalaCards organs/tissues related to Polysubstance Abuse:

40
Brain, Cortex, Prefrontal Cortex, Liver, Eye, Spinal Cord, Heart

Publications for Polysubstance Abuse

Articles related to Polysubstance Abuse:

(show top 50) (show all 323)
# Title Authors PMID Year
1
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 57 61
11704927 2001
2
Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. 57
23556448 2013
3
The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. 57
16972078 2006
4
A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. 57
15729709 2005
5
A missense mutation in human fatty acid amide hydrolase associated with problem drug use. 57
12060782 2002
6
Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. 61 54
16741937 2006
7
Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. 54 61
15289816 2004
8
Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. 54 61
11054766 2000
9
Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. 61 54
7704037 1994
10
Substance abuse vulnerability and D2 receptor genes. 61 54
7681236 1993
11
Polysubstance abuse among sexually abused in alcohol, drug, and gambling addiction treatment in Greenland: a cross sectional study. 61
33250010 2021
12
Global and glucocorticoid receptor gene-specific (NR3C1) DNA methylation analysis in patients with cannabinoid or synthetic cannabinoid use disorder. 61
33556690 2021
13
A Digital Health Tool to Understand and Prevent Cannabis-Impaired Driving Among Youth: A Cross-sectional Study of Responses to a Brief Intervention for Cannabis Use. 61
33650982 2021
14
A Case of Chronic Right Hip Pain Revealing an Insidious, Incidental Eight-Centimeter Internal Aneurysm Among Multiple Diffuse Aneurysms. 61
33604225 2021
15
An Unusual Case of COVID-19 Presenting as Acute Psychosis. 61
33280502 2020
16
Brodifacoum-Laced Synthetic Marijuana Toxicity: A Fight Against Time. 61
33132381 2020
17
Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B. 61
33096475 2020
18
Cesarean delivery in a parturient with a left ventricular assist device. 61
32799066 2020
19
Clinical Remission of Treatment-Resistant Depression, Polysubstance Abuse, and Antidepressant Discontinuation Syndrome Through Engagement of Lifestyle Interventions. 61
33186128 2020
20
Candida auris and endogenous panophthalmitis: clinical and histopathological features. 61
32462100 2020
21
Adolescent With Acute Liver Failure in the Setting of Ethanol, Cocaine, and Ecstasy Ingestion Treated With a Molecular Adsorbent Recirculating System. 61
32923289 2020
22
Case Report: A Polymicrobial Vision-Threatening Eye Infection Associated with Polysubstance Abuse. 61
32431277 2020
23
Critical Illness Secondary to Synthetic Cannabinoid Ingestion. 61
32687586 2020
24
Polysubstance abuse associated with more frequent opioid use among patients in rural primary care settings. 61
32885836 2020
25
Journey of the Nasal Septum Into the Lungs: A Unique Complication of Cocaine Abuse. 61
32821586 2020
26
Effects of Cocaine Exposure on Astrocytic Glutamate Transporters and Relapse-Like Ethanol-Drinking Behavior in Male Alcohol-Preferring Rats. 61
32099993 2020
27
Metastatic Lung Cancer Masquerading as Endophthalmitis. 61
32236164 2020
28
Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome. 61
33345989 2020
29
Coexistence of Substance Abuse among Emergency Department Patients Presenting with Suicidal Ideation. 61
33062697 2020
30
Cocaine, polysubstance abuse, and oral health outcomes, NHANES 2009 to 2014. 61
31919844 2020
31
Slow on the Uptake, Progression to Heartbreak. 61
32583694 2020
32
Substance abuse effects on urinary tract: methamphetamine and ketamine. 61
31796640 2019
33
Cocaine as a rare cause of locked-in syndrome: a case report. 61
31739807 2019
34
Abnormal Presentation of Hypoxic Ischemic Encephalopathy Attributed to Polysubstance Exposure. 61
31747388 2019
35
Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. 61
31268871 2019
36
Impact of psychosocial comorbidities on clinical outcomes after liver transplantation: Stratification of a high-risk population. 61
31528246 2019
37
Gluteal compartment syndrome following alcohol intoxication: Case report and literature review. 61
31360451 2019
38
Commentary on "A Call for Caution in Prescribing Gabapentin to Individuals with Concurrent Polysubstance Abuse: A Case Report". 61
31291213 2019
39
Marijuana Use in Pregnancy: A Review. 61
31343707 2019
40
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. 61
31291212 2019
41
Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal. 61
30961922 2019
42
Microsurgical Clip Reconstruction of Ruptured Dissecting PICA Aneurysm: 2-Dimensional Operative Video. 61
30872198 2019
43
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. 61
30758525 2019
44
Undifferentiated Shock and Extreme Elevation of Procalcitonin Related to Kratom Use. 61
31160844 2019
45
A Fatality Involving Furanylfentanyl and MMMP, with Presumptive Identification of Three MMMP Metabolites in Urine. 61
30566582 2019
46
Decompression Hemicraniectomy for Refractory Intracranial Hypertension in Reversible Cerebral Vasoconstriction Syndrome. 61
31001036 2019
47
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. 61
31329536 2019
48
Osteopathic Physical Exam Findings in Chronic Hepatitis C: A Case Study. 61
30937237 2019
49
Hydrops and fetal hypoplastic left heart: An unexpected improvement after cessation of maternal polysubstance abuse. 61
30194993 2018
50
Snow and Reindeer: Large Tricuspid Valve Mobile Vegetation. 61
30504520 2018

Variations for Polysubstance Abuse

Expression for Polysubstance Abuse

Search GEO for disease gene expression data for Polysubstance Abuse.

Pathways for Polysubstance Abuse

GO Terms for Polysubstance Abuse

Cellular components related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.33 DRD2 COMT CNR1
2 endocytic vesicle GO:0030139 9.32 DRD3 DRD2
3 integral component of presynaptic membrane GO:0099056 9.26 DRD2 CNR1
4 glutamatergic synapse GO:0098978 9.13 DRD3 DRD2 CNR1
5 GABA-ergic synapse GO:0098982 8.8 DRD3 DRD2 CNR1

Biological processes related to Polysubstance Abuse according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.81 DRD3 DRD2 COMT
2 response to ethanol GO:0045471 9.7 DRD3 DRD2 CNR1
3 cellular calcium ion homeostasis GO:0006874 9.68 DRD3 DRD2
4 locomotory behavior GO:0007626 9.68 DRD3 DRD2
5 circadian regulation of gene expression GO:0032922 9.67 DRD3 DRD2
6 learning or memory GO:0007611 9.67 DRD3 CNR1
7 negative regulation of protein kinase B signaling GO:0051898 9.67 DRD3 DRD2
8 learning GO:0007612 9.66 DRD3 COMT
9 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.66 DRD2 CNR1
10 visual learning GO:0008542 9.65 DRD3 DRD2
11 positive regulation of cytokinesis GO:0032467 9.65 DRD3 DRD2
12 response to nicotine GO:0035094 9.65 DRD2 CNR1
13 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.64 DRD3 DRD2
14 regulation of dopamine secretion GO:0014059 9.63 DRD3 DRD2
15 arachidonic acid secretion GO:0050482 9.63 DRD3 DRD2
16 negative regulation of protein secretion GO:0050709 9.62 DRD3 DRD2
17 negative regulation of adenylate cyclase activity GO:0007194 9.62 DRD3 DRD2
18 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.61 DRD3 DRD2
19 negative regulation of cytosolic calcium ion concentration GO:0051481 9.61 DRD3 DRD2
20 behavioral response to cocaine GO:0048148 9.6 DRD3 DRD2
21 positive regulation of renal sodium excretion GO:0035815 9.59 DRD3 DRD2
22 regulation of synaptic transmission, GABAergic GO:0032228 9.58 DRD2 CNR1
23 G protein-coupled receptor internalization GO:0002031 9.58 DRD3 DRD2
24 prepulse inhibition GO:0060134 9.57 DRD3 DRD2
25 synaptic transmission, dopaminergic GO:0001963 9.56 DRD3 DRD2
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.55 DRD3 DRD2
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.54 DRD3 DRD2
28 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.51 DRD3 DRD2
29 regulation of potassium ion transport GO:0043266 9.49 DRD3 DRD2
30 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.48 DRD3 DRD2
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.46 DRD3 DRD2
32 response to histamine GO:0034776 9.43 DRD3 DRD2
33 response to cocaine GO:0042220 9.43 DRD3 DRD2 CNR1
34 negative regulation of dopamine secretion GO:0033602 9.4 DRD2 CNR1
35 regulation of locomotion involved in locomotory behavior GO:0090325 9.37 DRD3 DRD2
36 response to morphine GO:0043278 9.33 DRD3 DRD2 CNR1
37 acid secretion GO:0046717 9.32 DRD3 DRD2
38 negative regulation of blood pressure GO:0045776 9.13 DRD3 DRD2 CNR1
39 dopamine metabolic process GO:0042417 8.8 DRD3 DRD2 COMT

Molecular functions related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
2 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.62 DRD3 DRD2

Sources for Polysubstance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....